Last updated: 2026-09-23 11:41:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Zhengye Biotechnology Holding Limited (ZYBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,33, with a market capitalization of $63,98M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,62 to $9,30. This page covers its latest market performance, valuation, price trends and company information.
$63,98M | |
$1,35 | |
$14,30 | |
$0,62 | |
$1,28 | |
847,00 | |
5,20M | |
-- | |
$9,30 | |
$0,62 | |
-- | |
-- |
Zhengye Biotechnology Holding Limited (ZYBT) is trading at $1,33 in pre-market trading as of 2026-09-23 11:38:00, up 3,91% ($0,05) from the previous close of $1,28
Pre-market trading shows how investors are pricing ZYBT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Zhengye Biotechnology Holding Limited (ZYBT) moved from $1,42 to $1,33, representing a decline of 6,34% ($0,09).
The stock traded between $1,26 and $1,55 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 29,72 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8,2%
ZYBT is currently trading at $1,33, placing it 8,2% of the way from its 52-week low of $0,62 to its 52-week high of $9,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
| Employees | 269 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zhengye Biotechnology Holding Limited (ZYBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.